Adaptive Radiotherapy for High-risk Prostate Cancer Using Multiparametric MRI

Launched by EAST AND NORTH HERTFORDSHIRE NHS TRUST · May 28, 2019

Keywords

ClinConnect Summary

Mount Vernon Cancer Centre at East and North Hertfordshire NHS Trust offers patients with certain cancers a treatment called adaptive radiotherapy. The aim of adaptive radiotherapy is to respond to physical changes that occur during treatment to ensure the radiation continues to be directed at the cancer and to minimise the amount of healthy tissue treated. For example, if tumour shrinkage or weight loss occurs during head and neck radiotherapy the patient may have a repeat CT scan and a new radiotherapy treatment plan after a few weeks of treatment. For patients with cancer of the bladder ...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• 1. New diagnosis of high-risk prostate cancer: any of:
• • 1. Gleason score of 8, 9 or 10
• • 2. PSA \> 20
• • 3. T3/4
• • 2. Patient due to receive androgen deprivation therapy (ADT)
• • 3. Prescribed 78Gy/39# external beam radiotherapy
• • 4. Measurable dominant intraprostatic tumour on diagnostic imaging of at least 10mm diameter
• • 5. ≥18 years of age
• • 6. ECOG performance status of 0-1
• • 7. Informed, written and witnessed consent to participate is required.
• Exclusion Criteria:
• • 1. Patients who are not due to receive androgen deprivation therapy (ADT)
• • 2. Any contraindication to MRI scanning including contraindication to MRI contrast agents
• • 3. Previous radiotherapy to the pelvis
• • 4. Any physical or social reasons that would make attendance for additional visits impossible.
• • 5. Any patient with or planned for prostate fiducial markers.
• • 6. Unable to give informed consent.
• • 7. Patients currently enrolled in an interventional clinical trial.